Patent: 8,591,897
✉ Email this page to a colleague
Summary for Patent: 8,591,897
Title: | Anti-ERBB2 antibody adjuvant therapy |
Abstract: | The present application describes adjuvant therapy of nonmetastatic breast cancer using HERCEPTIN.RTM.. |
Inventor(s): | Bryant; John L. (Allison Road, PA) |
Assignee: | Genentech, Inc. (South San Francisco, CA) |
Application Number: | 11/400,638 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,591,897 |
Patent Claims: | see list of patent claims |
Details for Patent 8,591,897
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 09/25/1998 | ⤷ Try a Trial | 2025-05-13 |
Genentech, Inc. | HERCEPTIN | trastuzumab | For Injection | 103792 | 02/10/2017 | ⤷ Try a Trial | 2025-05-13 |
Genentech, Inc. | HERCEPTIN HYLECTA | trastuzumab and hyaluronidase-oysk | Injection | 761106 | 02/28/2019 | ⤷ Try a Trial | 2025-05-13 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |